Clinical Practice

Use the tool below to view all available Global Oncology Academy Series

Managing Early Esophageal and Gastric Cancers: ASGE Recommendations on ESD and EMR
Managing Early Esophageal and Gastric Cancers: ASGE Recommendations on ESD and EMR
GI Insights
Managing Early Esophageal and Gastric Cancers: ASGE Recommendations on ESD and EMR
- Peter Buch, MD, FACG, AGAF, FACP
- Vivek Kaul, MD
Chemotherapy Strategies for Metastatic PDAC
Chemotherapy Strategies for Metastatic PDAC
MinuteCE®
Chemotherapy Strategies for Metastatic PDAC
0.25 program credits
- Efrat Dotan, MD
- Shubham Pant, MD, MBBS
0.25 program credits
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
Project Oncology®
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Matasar, MD
Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
Project Oncology®
Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
- Charles Turck, PharmD, BCPS, BCCCP
- Paolo Tarantino, MD
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
Project Oncology®
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
- Tara Graff, DO, MS
- Charles Turck, PharmD, BCPS, BCCCP
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Global Oncology Academy
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Project Oncology®
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
- Charles Turck, PharmD, BCPS, BCCCP
- Laura Alder, MD
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
MinuteCE®
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
1.25 program credits
- Sara Lonardi, MD
1.25 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
1.25 credits 10 episodes
- Sara Lonardi, MD
- Aparna R. Parikh, MD
- Alan Venook, MD
1.25 credits 10 episodes
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
1.50 credits 10 episodes
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 credits 10 episodes
Management of HER2-Low MBC Following First-Line Disease Progression
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
1.50 program credits
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
MinuteCE®
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
Management of HR+, HER2- High-Risk EBC
Management of HR+, HER2- High-Risk EBC
MinuteCE®
Management of HR+, HER2- High-Risk EBC
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits
The Evolving Treatment Landscape for MBC: Emerging Therapies
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
1.50 program credits
- William J. Gradishar, MD
1.50 program credits

Clinical Practice

Popular

NEED HELP?

Contact us

NEED HELP?

Contact us

Clinical Practice

Popular

Title

Share on ReachMD

Welcome to the newGlobal Oncology Academy website.

Welcome to the new
Global Oncology Academy website.